SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that new data from the Sightline study of Lung EpiCheck® will be presented by Dr. Peter Mazzone from Cleveland Clinic in a late-breaking rapid-fire original investigations session during the American College of Chest Physicians (CHEST) 2023 Annual Meeting, October 8-11 in Honolulu.
The presentation will showcase initial performance data from the Sightline study, a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients. Lung EpiCheck is being developed using markers discovered in Nucleix’s proprietary EpiCheck® Lung Atlas. The Lung Atlas is an early lung cancer detection discovery platform that was constructed and developed as part of a multi-institutional effort to map epigenetic and genetic changes associated with early-stage lung cancer, focusing on stage I disease.
Abstract Title: Enhanced detection of early-stage lung cancer with an ultrasensitive plasma-based methylation assay
Session Title: Late-Breaking Development in Lung Cancer, Lung Transplantation, and Pleural Disease
Presenter: Peter J. Mazzone, M.D., MPH, FCCP, Pulmonologist and Director, Lung Cancer Program, Respiratory Institute, Cleveland Clinic
Date: Tuesday, October 10
Time: 12:00 p.m. to 12:45 p.m. HST
The CHEST 2023 abstracts will be available on the journal CHEST website at: https://journal.chestnet.org/meetings.
About Nucleix
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases. For more information, please visit: https://www.nucleix.com.
NUCLEIX, the NUCLEIX Logo, and EPICHECK are trademarks or registered trademarks of Nucleix Ltd.
